Alexion wins 3 new Soliris patents as Amgen works on biosimilar of pricey drug

Soliris
Rare-disease drug Soliris is one of the most expensive drugs in the world, making it a prime target for biosimilars.

With a Soliris biosimilar showing up in its rearview mirror, Alexion is piling on patents for its superexpensive drug, hoping to put some more distance between it and any sales-grabbing copies.  

The New Haven, Connecticut-based drugmaker announced today that it has won three new patents for the rare-disease drug that are valid until 2027, six and seven years beyond its current EU and U.S. patent expirations. They cover its active ingredient eculizumab, its formulations and a method of treating the ultra rare, but potentially fatal, paroxysmal nocturnal hemoglobinuria.

“We continue to strengthen our patent portfolio around this unique complement inhibitor,” Ludwig Hantson, the recently appointed CEO, said in a statement. “These new patents work in concert with other patents and regulatory exclusivities to protect Soliris in all indications.”

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

RELATED: The top 20 drugs in 2020--worldwide sales – 8. Soliris

Soliris, which lists for more than $500,000 per patient year, is one of the most expensive drugs in the market and brought in more than $2.8 billion a year for the drugmaker. It is projected to hit up to $5.6 billion in sales by 2020. And U.S. biotech Amgen hopes to capture some of that cash when Soliris patents can be penetrated. Eculizumab is one of six biologics Amgen this year reported in its biosimilar pipeline.

RELATED: Alexion snags longtime Biogen vet and 'careful steward' Clancy to fill its CFO post

The threat comes at a difficult time for Alexion, which turned over pretty much its entire C-suite late last year after a sales fraud investigation that ultimately showed the company’s higher-ups had inappropriately pressured staff to pad sales of lead med Soliris. On top of that, federal investigators are looking at Alexion’s support of organizations that help Medicare patients and Brazilian authorities in May raided the company’s Sao Paulo, Brazil, offices as part of a probe into whether the company had subsidized lawsuits for patients to gain Soliris access.

RELATED: Which M&A made our best-and-worst ballot? Vote for the deals of the decade

Also, recently launched rare-disease med Kanuma, acquired in Alexion’s $8.4 billion Synageva buyout, has also been struggling mightily, prompting some FirecePharma readers to nominate that deal as one of the biggest duds of the decade.

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.